The Australasian Journal of Dermatology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Switch from adalimumab to brodalumab as a possible trigger factor for the onset of pyoderma gangrenosum
Australas J Dermatol. 2024 Apr 10. doi: 10.1111/ajd.14266. Online ahead of print.NO ABSTRACTPMID:38597123 | DOI:10.1111/ajd.14266 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - April 10, 2024 Category: Dermatology Authors: Giorgia Salvia Matteo Bevilacqua Flavia Manzo Margiotta Alessandra Michelucci Giammarco Granieri Cristian Fidanzi Valentina Dini Marco Romanelli Carlo Mazzatenta Source Type: research

Brodalumab for moderate-severe hidradenitis suppurativa: An open-label multicentric cohort study in real clinical practice
CONCLUSIONS: Brodalumab seems to be effective and safe in patients with moderate to severe HS, even in those that did not respond to adalimumab, which, at the moment, is the only widely approved biologic for this indication. Thus, it stands as an interesting option for the treatment of HS.PMID:38597096 | DOI:10.1111/ajd.14267 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - April 10, 2024 Category: Dermatology Authors: Guiovana Fernanda Osorio-G ómez Juan Ortiz- Álvarez Delia Diaz-Ceca Cesar Guijarro-S ánchez Juli án Conejo-Mir Sánchez Pablo Fern ández Crehuet Source Type: research

Efficacy and safety of tralokinumab in the treatment of head and neck pattern atopic dermatitis: A multicentre study of 12 patients
CONCLUSIONS: In real clinical practice, tralokinumab is demonstrated to be an effective and safe treatment for patients with AD and H&N pattern at short term.PMID:38587232 | DOI:10.1111/ajd.14264 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - April 8, 2024 Category: Dermatology Authors: Francisco Jos é Navarro-Triviño Mar ía Salazar-Nievas Juan Luis Sanz-Cabanillas Cintia Arjona-Aguilera Source Type: research

Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System
CONCLUSIONS: Our results suggest an association between SCARs and the ICIs independent of cancer status.PMID:38572842 | DOI:10.1111/ajd.14262 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - April 4, 2024 Category: Dermatology Authors: Hannah Godfrey Patrick Jedlowski Rebecca Thiede Source Type: research

Can we manage the melanocytic lesions with peripheral globules according to the grade of dysplasia?
CONCLUSIONS: To avoid the underdiagnosis of both melanomas and high-grade dysplastic nevi with PGs, the irregular shape of peripheral globules and multiple colours after the third decade may be useful in making an excision decision. The risk increases every 1-year increase in age. Excision is suggested for all melanocytic lesions with PGs for patients 60 years or older because of the high risk of melanoma and melanocytic nevus with high-grade dysplasia.PMID:38572867 | DOI:10.1111/ajd.14261 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - April 4, 2024 Category: Dermatology Authors: Ceylan Avc ı G ülfem Akın Banu Lebe Mustafa Turhan Şahin Emel Fetil Source Type: research

Extensive and deep granulomatous ulcers as an atypical manifestation of cartilage-hair hypoplasia syndrome: A diagnostic and therapeutic challenge
We present a case of a middle-aged man with cartilage hypoplasia syndrome featuring cutaneous granulomas, manifesting as chronic, extensive and deep cutaneous ulcers. The patient was treated with anti-TNF-alpha adalimumab with partial improvement. Our case underscores the broad spectrum of clinical manifestations associated with cartilage hypoplasia syndrome and adds new evidence to the potential therapeutic efficacy of anti-TNF-alpha drugs in its treatment.PMID:38544290 | DOI:10.1111/ajd.14258 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - March 28, 2024 Category: Dermatology Authors: Eduardo Rozas-Mu ñoz Rodrigo Blamey-Diaz Ana Maria Gallardo-Olivos Javiera Jerez Juan-Andres Madariaga Source Type: research